Key result
DOAC therapy for atrial fibrillation was associated with a 50% lower adjusted bleeding rate during the first month of treatment compared to therapy for venous thromboembolism (RR 0.5).
Why the study?
Does bleeding risk vary over time and differ between VTE and AF indications following initiation of direct oral anticoagulant therapy?
Does bleeding risk vary over time and differ between VTE and AF indications following initiation of direct oral anticoagulant therapy?
Relative Risk: 0.5 (95% CI 0.4–0.7)
Absolute Event Rate: 74.7% vs 140.8%
DOAC-associated bleeding risk is concentrated during the first month of treatment and is significantly higher in patients treated for VTE compared to AF, potentially reflecting the impact of higher-intensity initial loading doses.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Amber Afzal (2026) conducted an editorial in Atrial fibrillation or venous thromboembolism (n=2,663). DOAC therapy for atrial fibrillation vs. DOAC therapy for venous thromboembolism was evaluated on Adjusted bleeding rate during the first month of treatment (per 100 person-years) (RR 0.5, 95% CI 0.4-0.7). DOAC therapy for atrial fibrillation was associated with a 50% lower adjusted bleeding rate during the first month of treatment compared to therapy for venous thromboembolism (RR 0.5).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: